Heron Therapeutics Inc
HRTX.O- Latest Trade
- trading higher1.14USD
- 0.03
- 2.70%
- As of Jun 8 2023. Values delayed up to 15 minutes
- Today's Range
- 1.11 - 1.16
- 52 Week Range
- 1.07 - 5.62
- Previous Close
- 1.11
- Open
- 1.12
- Volume
- 1,295,113.00
- 3 Month Average Trading Volume
- 54.27
- Shares Out (Mil)
- 119.71
- Market Cap
- 134.08
- Forward P/E
- -1.27
- Dividend Yield
- 0.00
Key Statistics
1.83 mean rating - 6 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 1.18
- Price To Book (Quarterly)
- 0.00
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -93.24
- Return On Equity (TTM)
- -61.02
2021 (millions USD)
About Heron Therapeutics Inc (HRTX.O)
Company Information
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF, HTX-019, and HTX-034. HTX- ZYNRELEF is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting in adults. HTX-034 is a product candidate for postoperative pain management.
Address
4242 Campus Point Court, Suite 200SAN DIEGO, CA
92121
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Adam Morgan
- Chairman of the Board
- Craig Alexander Collard
- Chief Executive Officer, Director
- David L. Szekeres
- Chief Operating Officer, Executive Vice President
- Thomas B. Ottoboni
- Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer
- Sean T. Ristine
- Senior Vice President of Human Resources
- Robert Sullivan
- Senior Vice President
- Lisa Peraza
- Chief Accounting Officer, Vice President
- Jason Grillot
- Vice President of Sales and Marketing
- John Arthur
- Vice President - Manufacturing and Supply
- Laura R. Singer
- Vice President, Quality Assurance
- Christopher M. Storgard
- Chief Medical Officer
- Craig A. Johnson
- Lead Independent Director
- Sharmila Dissanaike
- Independent Director
- Kevin Kotler
- Independent Director
- Susan Rodriguez
- Independent Director
- Christian Waage
- Independent Director
Latest News
- MarketsGold stocks, Acer Therapeutics, Cvent, Apple, Jupiter Wellness
U.S. stock indexes slipped on Thursday after three straight days of gains following positive updates on the Omicron coronavirus variant, with focus now turning towards inflation data for clues on the Federal Reserve's policy decision.
- MarketsTwitter, Capri, Lucid Group, Amazon, Nuvei
U.S. stock indexes slipped on Thursday after three straight days of gains following positive updates on the Omicron coronavirus variant, with focus now turning towards economic data for clues on the Federal Reserve's policy decision.
- MarketsAmerican Airlines, GameStop, EVgo, Kinross Gold, SPI Energy
U.S. stock indexes were set to fall on Thursday after logging three straight days of gains on positive updates on the Omicron coronavirus variant, with focus now turning towards economic data for clues on the Federal Reserve's policy decision.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,965.90 | 1.19% |
| Copper | 724.80 | 0.52% |
| Brent Crude Oil | 76.58 | 0.48% |
| CBOT Soybeans | 1,368.50 | 0.57% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,275.60 | 0.19% |
| Euro STOXX 50 | 4,294.58 | 0.06% |
| FTSE 100 | 7,602.77 | 0.28% |
| Nikkei 225 | 31,641.27 | 0.85% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes